TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04177654

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.

Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
Study: NCT02077907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Sup

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Soy Blend 14 (CSB14) and fortified oil
Study: NCT03443492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin(oral )
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin(IV)
Description: Intervention is administered to patients in this Arm.
Study: NCT02033902

Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
Study: NCT02152618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Management Training - Oregon Model (PMTO)
Description: Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
Study: NCT00326872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Study: NCT02786160

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextropur
Study: NCT04044573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal Focal Laser Ablation (TPLA)
Description: The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
Study: NCT04467619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Proprioceptive Stimulation
Description: Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Proprioceptive Stimulation
Description: Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
Study: NCT00642993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 497079
Description: 100 mg capsule administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching SCH 497079 administered orally
Study: NCT00756171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam
Description: 2 times 3 625 mg tablets daily, 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times 3 625mg tablets daily
Study: NCT01112722

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Apitox, purified honeybee toxin, lyophilized in saline
Description: intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: histamine
Description: imitates pain and erythema of honeybee venom
Study: NCT03010657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will be asked to consume certain foods during chemotherapy treatment.
Study: NCT03498560

Intervention type: DEVICE
Intervention: PSG
Description: PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
Study: NCT02235558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
Study: NCT04342936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: A humanized monoclonal immunoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's choice of Chemotherapy
Description: Participants will receive one of the following chemotherapies for up to 6 cycles:~Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.
Study: NCT01525628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: CYP3A probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: nucleoside analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: CYP1A2 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: CYP2C9 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: CYP2C9 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: CYP3A probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: CYP1A2 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: CYP1A2 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: CYP2C9 probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: CYP3A probe drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: HCV protease inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: HCV polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: HCV treatment
Study: NCT01750827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB659032
Description: single dose
Study: NCT02803827

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid diagnostics
Description: Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid diagnostics
Description: Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Probiotic
Description: The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
Study: NCT03095534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-Step Workout for Life
Description: a 10-week moderate exercise program
Study: NCT01673048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Nail-ESIN in femoral shaft fractures
Study: NCT03636503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
Study: NCT06760247

Intervention type: PROCEDURE
Intervention: intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas
Description: endotracheal intubation by using direct laryngoscopy
Study: NCT03636503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
Study: NCT02803827

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be the vegetable oil vehicle and look identical to the probiotic.
Study: NCT03636503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04518600
Description: In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04518600
Description: In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
Study: NCT02803827

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: The placebo will be the vegetable oil vehicle and look identical to the probiotic.
Study: NCT03715751

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ASV
Description: Adaptive Support Ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lung Protective Ventilation
Description: Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
Study: NCT00989716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal glyceryl trinitrate patch
Description: 5mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-stroke antihypertensives
Description: Continue or stop pre-stroke anti-hypertensives
Study: NCT02117141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER 20 mg capsule (fasted)
Description: Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-ER 20 mg capsule (fed)
Description: Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
Study: NCT04094506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1948
Description: Intravenous
Study: NCT02733211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD- Logic Closed Loop System
Description: Closed Loop System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump therapy
Description: Sensor augmented pump therapy
Study: NCT03045198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study: NCT02607826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Starvation
Description: Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
Study: NCT01232660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400mg once daily orally
Study: NCT01600313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran oil
Description: Treatment group received the low - calorie diet with(30g/day) rice bran oil
Study: NCT01459380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT02096159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Study: NCT01459380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04785053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
Study: NCT02096159

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01646320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with Dapagliflozin
Description: Tablets, Oral, 0 mg, Once daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Once daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release (IR)
Description: Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release (IR)
Description: Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
Study: NCT04086771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information only
Description: American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
Study: NCT01457040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI+CY+VP-16
Description: CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FA+TBI+CY+VP-16
Description: NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10\~-6d; AraC: 1g/m2/d, -10d\~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
Study: NCT02460900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positively Smoke Free

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positively Smoke Free

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT01158378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adherus Dural Sealant
Description: In situ polymerizing sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adherus Dural Sealant
Description: In situ polymerizing sealant
Study: NCT02764775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headpod
Description: Adaptive equipment to assist with active head movements
Study: NCT04602494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: varenicline: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo: 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and starting on day 8, 1 mg twice daily for a total of 12 weeks
Study: NCT03325621

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRS-080#022-DP
Description: Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRS-080-Placebo#001
Description: Placebo Comparator